Anna V Mathew1, E Mitchell Seymour2, Jaeman Byun1, Subramaniam Pennathur3, Scott L Hummel4. 1. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 2. Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan. 3. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Ann Arbor Veterans Affairs Health System, Ann Arbor, Michigan. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Ann Arbor Veterans Affairs Health System, Ann Arbor, Michigan. Electronic address: scothumm@med.umich.edu.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a distinct entity with unique pathophysiology. In the Dietary Approaches to Stop Hypertension in Diastolic Heart Failure (DASH-DHF) study, the sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) was associated with improved blood pressure and cardiovascular function in 13 hypertensive patients with HFpEF. With the use of targeted metabolomics, we explored metabolite changes and their relationship with energy-dependent measures of cardiac function in DASH-DHF. METHODS AND RESULTS: With the use of chromatography and mass spectrometry, 152 metabolites including amino acids, free fatty acids, phospholipids, diglycerides, triglycerides, cholesterol esters, and acyl carnitines were measured. Comparison of baseline and post-DASH/SRD samples revealed increases in short-chain acetyl, butryl, and propionyl carnitines (P values .02, .03, .03, respectively). Increases in propionyl carnitine correlated with ventricular-arterial coupling ratio (Ees:Ea; r = 0.78; P = .005) and ventricular contractility (maximum rate of change of pressure-normalized stress [dσ*/dtmax]; r = 0.66; P = .03). Changes in L-carnitine also correlated with Ees:Ea (r = 0.62; P = .04) and dσ*/dtmax (r = 0.60; P = .05) and inversely with ventricular stiffness (r = -0.63; P = .03). CONCLUSIONS: Metabolite profile changes of patients with HFpEF during dietary modification with the use of DASH/SRD suggest improved energy substrate utilization. Additional studies are needed to clarify connections between diet, metabolic changes, and myocardial function in HFpEF. Published by Elsevier Inc.
BACKGROUND:Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a distinct entity with unique pathophysiology. In the Dietary Approaches to Stop Hypertension in Diastolic Heart Failure (DASH-DHF) study, the sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) was associated with improved blood pressure and cardiovascular function in 13 hypertensivepatients with HFpEF. With the use of targeted metabolomics, we explored metabolite changes and their relationship with energy-dependent measures of cardiac function in DASH-DHF. METHODS AND RESULTS: With the use of chromatography and mass spectrometry, 152 metabolites including amino acids, free fatty acids, phospholipids, diglycerides, triglycerides, cholesterol esters, and acyl carnitines were measured. Comparison of baseline and post-DASH/SRD samples revealed increases in short-chain acetyl, butryl, and propionyl carnitines (P values .02, .03, .03, respectively). Increases in propionyl carnitine correlated with ventricular-arterial coupling ratio (Ees:Ea; r = 0.78; P = .005) and ventricular contractility (maximum rate of change of pressure-normalized stress [dσ*/dtmax]; r = 0.66; P = .03). Changes in L-carnitine also correlated with Ees:Ea (r = 0.62; P = .04) and dσ*/dtmax (r = 0.60; P = .05) and inversely with ventricular stiffness (r = -0.63; P = .03). CONCLUSIONS: Metabolite profile changes of patients with HFpEF during dietary modification with the use of DASH/SRD suggest improved energy substrate utilization. Additional studies are needed to clarify connections between diet, metabolic changes, and myocardial function in HFpEF. Published by Elsevier Inc.
Authors: Scott L Hummel; E Mitchell Seymour; Robert D Brook; Theodore J Kolias; Samar S Sheth; Hannah R Rosenblum; Joanna M Wells; Alan B Weder Journal: Hypertension Date: 2012-10-01 Impact factor: 10.190
Authors: Liang Zhong; Kenneth K C Ng; Ling Ling Sim; John Carson Allen; Yee How Lau; David K L Sim; Raymond K K Lee; Kian Keong Poh; Terrance S J Chua; Ghassan S Kassab; Bernard W K Kwok; Ru San Tan Journal: Int J Cardiol Date: 2013-01-19 Impact factor: 4.164
Authors: Scott L Hummel; E Mitchell Seymour; Robert D Brook; Samar S Sheth; Erina Ghosh; Simeng Zhu; Alan B Weder; Sándor J Kovács; Theodore J Kolias Journal: Circ Heart Fail Date: 2013-08-28 Impact factor: 8.790
Authors: Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske Journal: Eur Heart J Date: 2014-08-07 Impact factor: 29.983
Authors: Beshay N Zordoky; Miranda M Sung; Justin Ezekowitz; Rupasri Mandal; Beomsoo Han; Trent C Bjorndahl; Souhaila Bouatra; Todd Anderson; Gavin Y Oudit; David S Wishart; Jason R B Dyck Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Nathan D Mathewson; Robert Jenq; Anna V Mathew; Mark Koenigsknecht; Alan Hanash; Vincent B Young; Subramaniam Pennathur; Marcel van den Brink; Tomomi Toubai; Katherine Oravecz-Wilson; Shin-Rong Wu; Yaping Sun; Corinne Rossi; Hideaki Fujiwara; Jaeman Byun; Yusuke Shono; Caroline Lindemans; Marco Calafiore; Thomas M Schmidt; Kenya Honda; Pavan Reddy Journal: Nat Immunol Date: 2016-03-21 Impact factor: 25.606